'The Top Line': 2022's top acquisitions and what Amgen's $28B Horizon buy means for M&A in 2023

2022’s slate of life sciences M&A deals didn’t meet expectations. But the year still featured tens of billions of dollars worth of biopharma acquisitions. Querida Anderson and Eric Sagonowsky discuss the top deals of the year. 

Also on the show, Kevin Dunleavy and Fraiser Kansteiner reflect on last year’s largest buyout—Amgen's $28 billion deal for Horizon Therapeutics. They explore what it potentially means for the buyer's market this year. Plus, this week's top headlines and Max Bayer's and Kansteiner's scoop on Johnson & Johnson's R&D overhaul and layoff plans.

To learn more about topics in this episode:

The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

To Listen to More Episodes from The Top Line